rss
Br J Ophthalmol 2003;87:629-632 doi:10.1136/bjo.87.5.629
  • Original Article
    • Laboratory science

Human uveal melanoma expresses NG2 immunoreactivity

  1. Y Li1,
  2. M C Madigan2,
  3. K Lai2,
  4. R M Conway2,
  5. F A Billson2,
  6. R Crouch3,
  7. B J Allen1,4
  1. 1Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray Street, Kogarah, NSW, Australia
  2. 2Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, NSW 2006, Australia
  3. 3Anatomical Pathology, Prince of Wales Hospital, Australia
  4. 4University of New South Wales, NSW 2052, Australia
  1. Correspondence to: Professor B J Allen, Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, 2217, Australia; b.allen{at}unsw.edu.au
  • Accepted 30 September 2002

Abstract

Background/aims: NG2 is the rat homologue of the human melanoma proteoglycan (HMP), also known as the high molecular weight melanoma associated antigen. Most cutaneous melanomas, as well as glioblastomas, chondrosarcomas, and some leukaemias express NG2 immunoreactivity, recognised using monoclonal antibody (mAb) 9.2.27. This antibody has also been used for molecular targeting in targeted α therapy for melanoma. The purpose of this study was to evaluate the expression of NG2 immunoreactivity in human uveal melanoma and normal ocular tissue using mAb 9.2.27.

Methods: Enucleated eyes from 26 patients with choroidal or ciliary body melanoma (n=26) were available as paraffin sections, and stained with haematoxylin and eosin to assess for tumour cell type and histopathology. Additional slides were investigated for NG2 immunoreactivity using mAb 9.2.27 and alkaline phosphatase anti-alkaline phosphatase (APAAP) immunostaining. Two independent observers graded immunostaining using a semiquantitative scale from 0 (negative) to 3 (strong).

Results: Immunostaining for mAb 9.2.27 could not be graded in 7/26 cases with dense pigmentation of the tumour. For the remaining cases, grade 2 (moderate) or more immunostaining was seen in 18/19 tumours (95%). The retina, retinal pigment epithelium (RPE), and choroid displayed weak immunostaining (grade 0.5–1.5) in the majority of melanoma affected eyes. Normal retina and choroid (n=5) appeared negative for mAb 9.2.27. Optic nerve axon bundles in both control and melanoma affected eyes displayed moderate immunostaining.

Conclusion: In the present study, the majority of human uveal melanomas expressed NG2 immunoreactivity, as detected using mAb 9.2.27. This antibody may be a suitable candidate for radioimmunotherapy to target ocular melanoma.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Services

    1. Email this link to a friend
    2. Alert me when this article is cited
    3. Alert me if a correction is posted
    4. Alert me when eletters are published
    5. Article Usage Statistics
    6. Similar articles in this journal
    7. Similar articles in Web of Science
    8. Similar articles in PubMed
    9. Add article to my folders
    10. Download to citation manager
    11. Request permissions

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
     This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.